TRIM2 Protein, Human
TRIM2, an UBE2D1-dependent E3 ubiquitin-protein ligase, mediates the ubiquitination of NEFL and phosphorylated BCL2L11. Beyond its ligase role, TRIM2 has neuroprotective functions and aids neuronal rapid ischemic tolerance. It crucially participates in antiviral immunity, restricting New World arenavirus infection. This highlights TRIM2's multifaceted involvement in cellular processes beyond ubiquitin-mediated protein degradation. TRIM2 Protein, Human is the recombinant human-derived TRIM2 protein, expressed by E. coli , with tag free.
- Species: Human
- Source: E. coli
Biological Activity
TRIM2, an UBE2D1-dependent E3 ubiquitin-protein ligase, mediates the ubiquitination of NEFL and phosphorylated BCL2L11. Beyond its ligase role, TRIM2 has neuroprotective functions and aids neuronal rapid ischemic tolerance. It crucially participates in antiviral immunity, restricting New World arenavirus infection. This highlights TRIM2's multifaceted involvement in cellular processes beyond ubiquitin-mediated protein degradation. TRIM2 Protein, Human is the recombinant human-derived TRIM2 protein, expressed by E. coli , with tag free.
TRIM2, an UBE2D1-dependent E3 ubiquitin-protein ligase, serves as a mediator for the ubiquitination of NEFL and phosphorylated BCL2L11. Beyond its role in ubiquitin ligase activity, TRIM2 exhibits a neuroprotective function and may contribute to neuronal rapid ischemic tolerance. Furthermore, it plays a crucial role in antiviral immunity and acts as a restrictor of New World arenavirus infection, emphasizing its multifaceted involvement in cellular processes beyond ubiquitin-mediated protein degradation.
Technical Parameters
-
Species Human
-
Source E. coli
-
Tag Tag Free
-
Accession
Q9C040 (A2-Q744)
-
Gene ID23321
-
Molecular Construction
-
N-term
-
TRIM2 (A2-Q744)
Accession # Q9C040 -
C-term
-
-
Protein Length
Partial
-
Synonyms
TRIM2; Tripartite motif-containing protein 2; E3 ubiquitin-protein ligase TRIM2; RING finger protein 86; RING-type E3 ubiquitin transferase TRIM2
-
AA Sequence
ASEGTNIPSPVVRQIDKQFLICSICLERYKNPKVLPCLHTFCERCLQNYIPAHSLTLSCPVCRQTSILPEKGVAALQNNFFITNLMDVLQRTPGSNAEESSILETVTAVAAGKPLSCPNHDGNVMEFYCQSCETAMCRECTEGEHAEHPTVPLKDVVEQHKASLQVQLDAVNKRLPEIDSALQFISEIIHQLTNQKASIVDDIHSTFDELQKTLNVRKSVLLMELEVNYGLKHKVLQSQLDTLLQGQESIKSCSNFTAQALNHGTETEVLLVKKQMSEKLNELADQDFPLHPRENDQLDFIVETEGLKKSIHNLGTILTTNAVASETVATGEGLRQTIIGQPMSVTITTKDKDGELCKTGNAYLTAELSTPDGSVADGEILDNKNGTYEFLYTVQKEGDFTLSLRLYDQHIRGSPFKLKVIRSADVSPTTEGVKRRVKSPGSGHVKQKAVKRPASMYSTGKRKENPIEDDLIFRVGTKGRNKGEFTNLQGVAASTNGKILIADSNNQCVQIFSNDGQFKSRFGIRGRSPGQLQRPTGVAVHPSGDIIIADYDNKWVSIFSSDGKFKTKIGSGKLMGPKGVSVDRNGHIIVVDNKACCVFIFQPNGKIVTRFGSRGNGDRQFAGPHFAAVNSNNEIIITDFHNHSVKVFNQEGEFMLKFGSNGEGNGQFNAPTGVAVDSNGNIIVADWGNSRIQVFDGSGSFLSYINTSADPLYGPQGLALTSDGHVVVADSGNHCFKVYRYLQ
-
Purity
≥ 85%, as determined by reducing SDS-PAGE.
Documentation
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)